Glycemic Control (HbA1c Reduction)

•     Ketogenic Diet: Studies show HbA1c reductions typically range from 1-2%, with some cases achieving up to 3.3% in 12 weeks. However, results vary based on adherence.
•     Specific studies showed reductions like from 8.9% to 5.6% in 90 days (3.3% reduction, p<0.0001) and from 7.8% to 6.3% in 24 weeks (1.5% reduction, p<0.0001), as detailed in "Efficacy of Ketogenic Diets on Type 2 Diabetes".
•     Read more: https://pmc.ncbi.nlm.nih.gov/articles/PMC8397683/
  

    Tirzepatide: Clinical trials indicate consistent reductions of 2-2.3% over 40 weeks, offering predictable outcomes.
    Clinical trials, particularly the SURPASS program, demonstrate robust HbA1c reductions. In SURPASS-2, "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes", over 40 weeks, tirzepatide at 5 mg, 10 mg, and 15 mg reduced HbA1c by 2.01%, 2.24%, and 2.30% respectively, compared to 1.86% with semaglutide 1 mg, with significant differences (p<0.001 for 10 mg and 15 mg). Another review, "Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective", noted reductions of -1.87 to -2.59% (-20 to -28 mmol/mol) across SURPASS 1-5 trials, with consistent outcomes. FDA approval data from GoodRx, "FDA Approves Mounjaro (tirzepatide) Injection for Diabetes", confirms an average 2% reduction, aligning with trial data.